Curia 扩大格拉斯哥产能并改进细胞系开发平台

Core Insights - Curia announced the progress of its sterile drug manufacturing facility expansion in Glasgow, UK, which is expected to be completed by early 2027 [1] - The expansion will add a new isolator-based vial filling line and a lyophilizer, increasing the filling capacity to a maximum of 20,000 vials per batch [1] - Curia's improvements to its cell line development (CLD) platform will enhance its clinical active pharmaceutical ingredient development capabilities [1] Group 1: Facility Expansion - The Glasgow facility has over 25 years of experience in formulation, lyophilization development, and sterile filling, making it well-regarded in the industry [1] - The expansion is designed to support future small-scale commercial filling needs and will not disrupt existing operations during the construction phase [1] Group 2: Technology Advancements - Curia's CLD platform has been upgraded with a non-IP restrictive semi-targeted integration technology, resulting in a sixfold increase in titer compared to random integration technology [1] - The stable platform CHO-GSN® and the transient expression platform TunaCHO® are derived from the same parent cell line, facilitating efficient scale-up from R&D to GMP-compliant production [1][2] Group 3: Company Overview - Curia is a contract research, development, and manufacturing organization (CDMO) with over 30 years of experience and a global network of facilities [2] - The company employs over 3,100 people and collaborates with biopharmaceutical clients to bring life-changing therapies to market [2]